Cisplatin-incorporating polymeric micelles (NC-6004) can reduce nephrotoxicity and neurotoxicity of cisplatin in rats
Open accessThe DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Abstract
In spite of the clinical usefulness of cisplatin (CDDP), there are many occasions in which it is difficult to continue the administration of CDDP due to its nephrotoxicity and neurotoxicity. We examined the incorporation of CDDP into polymeric micelles to see if this allowed the resolution of these disadvantages. Cisplatin was incorporated into polymeric micelles through the polymer-metal complex formation between polyethylene glycol poly(glutamic acid) block copolymers and CDDP (NC-6004). The pharmacokinetics, pharmacodynamics, and toxicity studies of CDDP and NC-6004 were conducted in rats or mice. The particle size of NC-6004 was approximately 30 nm, with a narrow size distribution. In rats, the area under the curve and total body clearance values for NC-6004 were 65-fold and one-nineteenth the values for CDDP (P<0.001 and 0.01, respectively). In MKN-45-implanted mice, NC-6004 tended to show antitumour activity, which was comparable to or greater than that of CDDP. Histopathological and biochemical studies revealed that NC-6004 significantly inhibited the nephrotoxicity of CDDP. On the other hand, blood biochemistry revealed transient hepatotoxicity on day 7 after the administration of NC-6004. Furthermore, rats given CDDP showed a significant delay (P<0.05) in sensory nerve conduction velocity in their hind paws as compared with rats given NC-6004. Electron microscopy in rats given CDDP indicated the degeneration of the sciatic nerve, but these findings were not seen in rats given NC-6004. These results were presumably attributable to the significantly reduced accumulation of platinum in nerve tissue when NC-6004 was administered (P<0.05). NC-6004 preserved the antitumour activity of CDDP and reduced its nephrotoxicity and neurotoxicity, which would therefore seem to suggest that NC-6004 could allow the long-term administration of CDDP where caution against hepatic dysfunction must be exercised.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“NC-6004 exhibited stable micelles in solution and slowly released cisplatin from the micelle for over 150 h in physiological saline. NC-6004 exhibited a narrow size distribution in solution with a size of 28 nm and loading of cisplatin in NC-6004 was up to 39% LC [153].”
From Polymeric micelles for the delivery of poorly soluble drugs: From nanoformulation to clinical approval. (2020) · cites this paper as [153]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“A similar polymeric micelle formulation where CDDP was coordinated with PEG-b-P(Glu) [153] evolved into a clinically evaluated polymeric micelle drug, NC-6004 which is described below in Section 5.3.”
From Polymeric micelles for the delivery of poorly soluble drugs: From nanoformulation to clinical approval. (2020) · cites this paper as [153]
The cited source says what the claim attributes to it.
In the citing paper
“Originally developed by Kataoka’s group and NanoCarrier Co., Ltd., NC-6004 is a cisplatin-containing polymeric micelle formed via coordination of platinum drug with the P(Glu) segment of the PEG-b-P(Glu) block copolymer (PEG: 12,000 g/mol and P(Glu): 6,000 g/mol) [153].”
From Polymeric micelles for the delivery of poorly soluble drugs: From nanoformulation to clinical approval. (2020) · cites this paper as [153]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Matsumura, Y., & Maeda, H. (1986) · PubMed · Cited by 6,781
Self-citationTumor vascular permeability and the EPR effect in macromolecular therapeutics: a review
Maeda, H., Wu, J., Sawa, T., Matsumura, Y., & Hori, K. (2000) · Journal of Controlled Release · doi:10.1016/s0168-3659(99)00248-5 · Cited by 6,565
Self-citationMaeda, H. (2001) · Advances in Enzyme Regulation · doi:10.1016/s0065-2571(00)00013-3 · Cited by 2,495 · cited 1×
“…polymers or nanoparticles, which are less prone to leak from intact vasculature, and which can be retained in solid tumour tissue for a longer time (enhanced permeability and retention effect (EPR) effect) (Matsumura and Maeda, 1986; Maeda and Matsumura, 1989; Maeda, 2000, 2001).”
BackgroundAmphipathic polyethyleneglycols effectively prolong the circulation time of liposomes
Klibanov, A. L., Maruyama, K., Torchilin, V. P., & Huang, L. (1990) · FEBS Letters · doi:10.1016/0014-5793(90)81016-h · Cited by 2,027 · cited 1×
“…93, 678 – 687 & 2005 Cancer Research UK All rights reserved 0007 – 0920/05 $30.00 www.bjcancer.com T ra n sla tio n a l T h e ra p e u tic s the reticuloendothelial system (RES) and to enhance the blood retention profile (Klibanov et al, 1990, 1991; Allen, 1994; Gabizon etal, 1996; Lasic, 1996).”
BackgroundInfluentialdu Bois, A. (2003) · CancerSpectrum Knowledge Environment · doi:10.1093/jnci/djg036 · Cited by 1,113 · cited 1×
“Consequently, these analogues are becoming the standard drugs for ovarian cancer (du Bois et al, 2003) and colon cancer (Cassidy et al, 2004).”
BackgroundNovel cisplatin-incorporated polymeric micelles can eradicate solid tumors in mice.
Nishiyama, N., Okazaki, S., Cabral, H., Miyamoto, M., Kato, Y., Sugiyama, Y., Nishio, K., Matsumura, Y., & Kataoka, K. (2003) · PubMed · Cited by 710
Self-citation(1998) · British Journal of Cancer · doi:10.1038/bjc.1998.1 · Cited by 654
Phase I clinical trial and pharmacokinetic evaluation of NK911, a micelle-encapsulated doxorubicin
Matsumura, Y., Hamaguchi, T., Ura, T., Muro, K., Yamada, Y., Shimada, Y., Shirao, K., Okusaka, T., Ueno, H., Ikeda, M., et al. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6602204 · Cited by 623 · cited 1×
“The Phase I clinical trial of adriamycin-incorporating polymeric micelles has been completed (Matsumura et al, 2004).”
BackgroundSelf-citationHamaguchi, T., Matsumura, Y., Suzuki, M., Shimizu, K., Goda, R., Nakamura, I., Nakatomi, I., Yokoyama, M., Kataoka, K., & Kakizoe, T. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602479 · Cited by 565
Self-citationCassidy, J., Tabernero, J., Twelves, C., Brunet, R., Butts, C., Conroy, T., Debraud, F., Figer, A., Grossmann, J., Sawada, N., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.11.069 · Cited by 525 · cited 1×
“Consequently, these analogues are becoming the standard drugs for ovarian cancer (du Bois et al, 2003) and colon cancer (Cassidy et al, 2004).”
Background
Cited by
Items 101–200 of 432
Oberoi, H. S., Laquer, F. C., Marky, L. A., Kabanov, A. V., & Bronich, T. K. (2011) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.03.028 · Cited by 94
pH-Responsive Nanoparticles for Cancer Drug Delivery
Shen, Y., Tang, H., Radosz, M., Kirk, E. V., & Murdoch, W. J. (2008) · Methods in molecular biology · doi:10.1007/978-1-59745-210-6_10 · Cited by 105
Xie, Y., Aillon, K. L., Cai, S., Christian, J. M., Davies, N. M., Berkland, C. J., & Forrest, M. L. (2010) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2010.03.058 · Cited by 93
“These pharmacokinetic parameters were very similar to the results of free CDDP and CDDP-incorporating PEG-P(Glu) micelles using the same noncompartment model (Uchino et al., 2005).”
ResultYang, J. J., Liu, W., Sui, M., Tang, J., & Shen, Y. (2011) · Biomaterials · doi:10.1016/j.biomaterials.2011.08.022 · Cited by 93
Greish, K. F. (2011) · Drug Discovery Today Technologies · doi:10.1016/j.ddtec.2011.11.010 · Cited by 104
Negishi, T., Koizumi, F., Uchino, H., Kuroda, J., Kawaguchi, T., Naito, S., & Matsumura, Y. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603311 · Cited by 92
“We demonstrated that the incorporation of cisplatin into micelles significantly reduced the nephrotoxicity and neurotoxicity of cisplatin (Uchino et al, 2005).”
BackgroundSelf-citationOvercoming the road blocks: advancement of block copolymer micelles for cancer therapy in the clinic
Houdaihed, L., Evans, J. C., & Allen, C. (2017) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.7b00188 · Cited by 91
Lee, D. Y., Kim, J. Y., Lee, Y., Lee, S., Miao, W., Kim, H. S., Min, J., & Jon, S. (2017) · Angewandte Chemie International Edition · doi:10.1002/anie.201707137 · Cited by 91
Huang, C., Neoh, K. G., Xu, L., Kang, E. T., & Chiong, E. (2012) · Biomacromolecules · doi:10.1021/bm300739w · Cited by 90
Zhang, J., Ellsworth, K., & Ma, P. X. (2010) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.04.019 · Cited by 91
“Several micellar formulations of antitumor drugs have been intensively studied in preclinical and clinical trials, and their efficacy has been demonstrated [12–15].”
BackgroundFactors affecting toxicity and efficacy of polymeric nanomedicines
Igarashi, E. (2008) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2008.02.007 · Cited by 104
Nanogels: A chemically versatile drug delivery platform
Blagojevic, L., & Kamaly, N. (2025) · Nano Today · doi:10.1016/j.nantod.2025.102645 · Cited by 94
Xie, J., Tan, R. S., & Wang, C. (2008) · Journal of Biomedical Materials Research Part A · doi:10.1002/jbm.a.31499 · Cited by 84
Optimizing pharmacokinetics of intravesical chemotherapy for bladder cancer
Joice, G. A., Bivalacqua, T. J., & Kates, M. R. (2019) · Nature Reviews Urology · doi:10.1038/s41585-019-0220-4 · Cited by 88
The Drug Discovery by NanoMedicine and its Clinical Experience
Matsumura, Y. (2014) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyu046 · Cited by 80
Self-citationRecent advances in prodrug-based nanoparticle therapeutics
Chen, K., Plaunt, A. J., Leifer, F., Kang, J. Y., & Cipolla, D. C. (2021) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2021.04.025 · Cited by 86
Polypeptides–Drug Conjugates for Anticancer Therapy
Zhang, Y. X., He, P., Zhang, P., Yi, X., Xiao, C., & Chen, X. (2021) · Advanced Healthcare Materials · doi:10.1002/adhm.202001974 · Cited by 80
Stimulus-Responsive Targeted Nanomicelles for Effective Cancer Therapy
Muthu, M. S., Rajesh, C. V., Mishra, A., & Singh, S. (2009) · Nanomedicine · doi:10.2217/nnm.09.44 · Cited by 81
Mesoporous silica nanoparticles for the improved anticancer efficacy of cis-platin
Lin, C., Cheng, S., Liao, W., Wei, P., Sung, P., Weng, C., & Lee, C. (2012) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2012.03.026 · Cited by 78
Combination Chemotherapeutic Dry Powder Aerosols via Controlled Nanoparticle Agglomeration
El-Gendy, N. A., & Berkland, C. J. (2009) · Pharmaceutical Research · doi:10.1007/s11095-009-9886-2 · Cited by 78
“4) using an atomic absorption spectrophotometer (Spectra AA 220G, Varian) (36,37,48).”
MethodInfluentialDisposition of Drugs in Block Copolymer Micelle Delivery Systems: From Discovery to Recovery
Aliabadi, H. M., Shahin, M., Brocks, D. R., & Lavasanifar, A. (2008) · Clinical Pharmacokinetics · doi:10.2165/00003088-200847100-00001 · Cited by 84
Xue, X., Hall, M. D., Zhang, Q., Wang, P. C., Gottesman, M. M., & Liang, X. (2013) · ACS Nano · doi:10.1021/nn405004f · Cited by 80
Micellization of cisplatin (NC-6004) reduces its ototoxicity in guinea pigs
Baba, M., Matsumoto, Y., Kashio, A., Cabral, H., Nishiyama, N., Kataoka, K., & Yamasoba, T. (2011) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.07.026 · Cited by 79
Self-citationYe, L., Letchford, K., Heller, M., Liggins, R., Guan, D., Kizhakkedathu, J. N., Brooks, D. E., Jackson, J. K., & Burt, H. M. (2010) · Biomacromolecules · doi:10.1021/bm101080p · Cited by 77
Encapsulation of a Hydrophobic Drug into a Polymer-Micelle Core Explored with Synchrotron SAXS
Akiba, I., Terada, N., Hashida, S., Sakurai, K., Sato, T., Shiraishi, K., Yokoyama, M., Masunaga, H., Ogawa, H., Ito, K., et al. (2010) · Langmuir · doi:10.1021/la904355p · Cited by 76
Inoue, T., Yamashita, Y., Nishihara, M., Sugiyama, S., Sonoda, Y., Kumabe, T., Yokoyama, M., & Tominaga, T. (2009) · Neuro-Oncology · doi:10.1215/15228517-2008-068 · Cited by 79
Sakai-Kato, K., Nishiyama, N., Kozaki, M., Nakanishi, T., Matsuda, Y., Hirano, M., Hanada, H., Hisada, S., Onodera, H., Harashima, H., et al. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.05.259 · Cited by 75
Self-citationPolyamide/Poly(Amino Acid) Polymers for Drug Delivery
Boddu, S. H. S., Bhagav, P., Karla, P. K., Jacob, S., Adatiya, M. D., Dhameliya, T. M., Ranch, K. M., & Tiwari, A. K. (2021) · Journal of Functional Biomaterials · doi:10.3390/jfb12040058 · Cited by 83
“This was attributed to an inverse ligand substitution of Pt (II) atom from a glutamate residue of PEG-P(Glu) to chloride [46].”
BackgroundMethodInfluentialStimuli-responsive nanocarrier delivery systems for Pt-based antitumor complexes: a review
Wang, T., Wu, C., Hu, Y., Zhang, Y., & Ma, J. (2023) · RSC Advances · doi:10.1039/d3ra00866e · Cited by 90
van (2010) · International Journal of Nanomedicine · doi:10.2147/ijn.s13482 · Cited by 79
Nucleoside–Lipid-Based Nanoparticles for Cisplatin Delivery
Khiati, S., Luvino, D., Oumzil, K., Chauffert, B., Camplo, M., & Barthélémy, P. (2011) · ACS Nano · doi:10.1021/nn202291k · Cited by 74
Multifunctional Polymeric Micelles for Cancer Therapy
Jin, G., Rejinold, N. S., & Choy, J. (2022) · Polymers · doi:10.3390/polym14224839 · Cited by 77
“Laboratory experiments confirmed the safety of NC-6004 in terms of lowering the nephrotoxicity and neurotoxicity more than the intact cisplatin at an equivalent dose [80].”
BackgroundCallari, M., De Souza, P. L., Rawal, A., & Stenzel, M. H. (2017) · Angewandte Chemie International Edition · doi:10.1002/anie.201701471 · Cited by 68
Copolymers: Efficient Carriers for Intelligent Nanoparticulate Drug Targeting and Gene Therapy
Hamidi, M., Shahbazi, M., & Rostamizadeh, K. (2011) · Macromolecular Bioscience · doi:10.1002/mabi.201100193 · Cited by 80
Fan, X., Zhao, X., Qu, X., & Fang, J. Q. (2015) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2015.10.066 · Cited by 67
The in vitro biocompatibility of self-assembled hyperbranched copolyphosphate nanocarriers
Liu, J., Huang, W., Pang, Y., Zhu, X., Zhou, Y., & Yan, D. (2010) · Biomaterials · doi:10.1016/j.biomaterials.2010.03.068 · Cited by 68
Biological activity of amphiphilic metal complexes
Schattschneider, C., Kettenmann, S. D., Hinojosa, S., Heinrich, J., & Kulak, N. (2019) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2018.12.007 · Cited by 68
Multifunctional polymeric micellar nanomedicine in the diagnosis and treatment of cancer
Raval, N., Maheshwari, R., Shukla, H., Kalia, K., Torchilin, V. P., & Tekade, R. K. (2021) · Materials Science and Engineering C · doi:10.1016/j.msec.2021.112186 · Cited by 68
Miki, K., Oride, K., Inoue, S., Kuramochi, Y., Nayak, R. R., Matsuoka, H., Harada, H., Hiraoka, M., & Ohe, K. (2009) · Biomaterials · doi:10.1016/j.biomaterials.2009.10.005 · Cited by 67
Polymeric micelles for targeted tumor therapy of platinum anticancer drugs
Mochida, Y., Cabral, H., & Kataoka, K. (2017) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2017.1307338 · Cited by 64
“The CDDP/m remarkably reduced nephrotoxicity of cisplatin in rats, which is the main problem of cisplatin limiting administration dose in clinical practice [60].”
BackgroundSelf-citationLHRH-targeted nanogels as a delivery system for cisplatin to ovarian cancer
Nukolova, N. V., Oberoi, H. S., Zhao, Y., Chekhonin, V. P., Kabanov, A. V., & Bronich, T. K. (2013) · Molecular Pharmaceutics · doi:10.1021/mp4003688 · Cited by 63
Azadirachta indica attenuates cisplatin-induced neurotoxicity in rats
Moneim, A. E. A. (2014) · Indian Journal of Pharmacology · doi:10.4103/0253-7613.132182 · Cited by 62
“injection of CP (5 mg/kg bwt) was chosen according to Uchino et al.[10] and Kamisli et al.”
Song, W., Tang, Z., Shen, N., Yu, H., Jia, Y., Zhang, D., Jiang, J. W., He, C., Tian, H., & Chen, X. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.02.039 · Cited by 65
Targeted delivery of platinum-taxane combination therapy in ovarian cancer
Desale, S. S., Soni, K. S., Romanova, S., Cohen, S. M., & Bronich, T. K. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.09.007 · Cited by 61
Overcoming tumor resistance to cisplatin by cationic lipid-assisted prodrug nanoparticles
Cao, Z., Chen, Z., Sun, C., Li, H., Wang, H., Cheng, Q., Zuo, Z.-Q., Wang, J., Liu, Y., Wang, Y., et al. (2016) · Biomaterials · doi:10.1016/j.biomaterials.2016.04.001 · Cited by 63
Yang, X., Yu, Y., Huang, X., Chen, Q., Wu, H., Wang, R., Qi, R., Miao, Y., & Qiu, Y. (2018) · Materials Science and Engineering C · doi:10.1016/j.msec.2018.10.092 · Cited by 64
Lv, S., Song, W., Tang, Z., Li, M., Yu, H., Hong, H., & Chen, X. (2014) · Molecular Pharmaceutics · doi:10.1021/mp4007387 · Cited by 62
Kates, M. R., Date, A. A., Yoshida, T., Afzal, U., Kanvinde, P. P., Babu, T., Sopko, N. A., Matsui, H., Hahn, N. M., McConkey, D. J., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1082 · Cited by 60
Shi, C., Yu, H., Sun, D., Ma, L., Tang, Z., Xiao, Q., & Chen, X. (2015) · Acta Biomaterialia · doi:10.1016/j.actbio.2015.02.009 · Cited by 61
“8-fold lower in animals given NC-6004 than in animals given CDDP [12].”
BackgroundClinical Translation of Self‐Assembled Cancer Nanomedicines
Mi, P., Miyata, K., Kataoka, K., & Cabral, H. (2020) · Advanced Therapeutics · doi:10.1002/adtp.202000159 · Cited by 65
Self-citationOliveira, M. C., Leite, E., Souza, Carvalho-Junior, Coelho, Lana, Â. M. Q., & Cassali, G. D. (2012) · International Journal of Nanomedicine · doi:10.2147/ijn.s34652 · Cited by 57
“6 The present study’s research group has developed long-circulating and pH-sensitive liposomes containing CDDP (SpHL-CDDP) which previously showed both two-and three-fold higher values of median lethal doses than those obtained for free CDDP after their intravenous (IV) and intraperitoneal…”
Wang, Y., Liu, P., Qiu, L., Sun, Y., Zhu, M., Gu, L., Di, W. J., & Duan, Y. (2013) · Biomaterials · doi:10.1016/j.biomaterials.2012.12.033 · Cited by 56
“CDDP is an effective chemotherapy drug, which is widely used to treat ovarian cancer, but it lacks specificity for ovarian carcinoma and can easily induce severe side effects such as gastrointestinal adverse reaction, acute nephrotoxicity and chronic neurotoxicity [4].”
BackgroundPolymeric nano-micelles: Versatile Platform for Targeted Delivery in Cancer
Mohamed, S. E.-S. H., Parayath, N. N., Taurin, S., & Greish, K. F. (2014) · Therapeutic Delivery · doi:10.4155/tde.14.69 · Cited by 61
Cooper, D. L., Conder, C. M., & Harirforoosh, S. (2014) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2014.938046 · Cited by 68
“Cisplatin Chemotherapeutic Various cancers Prolonged anti-tumor effects, reduced nephrotoxic side effects in human clinical trials, reduce drug accumulation within kidneys, reduction in kidney cell death [121-124]”
BackgroundShirbin, S. J., Ladewig, K., Fu, Q., Klimak, M., Zhang, X., Duan, W., & Qiao, G. G. (2015) · Biomacromolecules · doi:10.1021/acs.biomac.5b00692 · Cited by 60
Polymeric drug delivery systems for intraoral site‐specific chemoprevention of oral cancer
Desai, K. G. H. (2017) · Journal of Biomedical Materials Research Part B Applied Biomaterials · doi:10.1002/jbm.b.33943 · Cited by 59
Self-Assembled Nanogels Based on Ionic Gelation of Natural Polysaccharides for Drug Delivery
Wang, H., Deng, H., Gao, M., & Zhang, W. (2021) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2021.703559 · Cited by 61
Combination Therapies and Drug Delivery Platforms in Combating Pancreatic Cancer
Lei, F., Xi, X., Batra, S. K., & Bronich, T. K. (2019) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.118.255786 · Cited by 51
“Preclinical studies have indicated that NC-6004 exhibited prolonged blood circulation, preferential distribution to tumors, significantly lowered toxicity levels (compared with cisplatin at equivalent doses), and increased antitumor activity (Uchino et al., 2005; Cabral et al., 2011; Baba et al., 2012).”
BackgroundThe potential of polymeric micelles in the context of glioblastoma therapy
Morshed, R. A., Cheng, Y., Auffinger, B., Wegscheid, M. L., & Lesniak, M. S. (2013) · Frontiers in Pharmacology · doi:10.3389/fphar.2013.00157 · Cited by 56
“NC-6004 led to significant anti-tumor effects in a mouse model of colon adenocarcinoma 26, human gastric cancer (MKN-45) bearing mice, and in HT29 oxaliplatin-resistant bearing mice (Nishiyama et al., 2003; Uchino et al., 2005; Alami et al., 2006).”
BackgroundFirst polymer “ruthenium-cyclopentadienyl” complex as potential anticancer agent
Valente, A., García, M. H., Marques, F., Miao, Y., Rousseau, C., & Zinck, P. (2013) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2013.07.002 · Cited by 51
Nanoparticles Effectively Target Rapamycin Delivery to Sites of Experimental Aortic Aneurysm in Rats
Shirasu, T., Koyama, H., Miura, Y., Hoshina, K., Kataoka, K., & Watanabe, T. (2016) · PLoS ONE · doi:10.1371/journal.pone.0157813 · Cited by 55
Self-citationYu, W., Zhu, J., Wang, Y., Wang, J., Fang, W., Xia, K., Shao, J., Wu, M.-Z., Liu, B., Liang, C., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.16243 · Cited by 53
“2) NPs of the appropriate size spend a longer time circulating in plasma with less elimination [100] and 3) less elimination in other organs leads to the reduction of cytotoxicity in other organs [101].”
BackgroundSiemer, S., Bauer, T. A., Scholz, P., Breder, C., Fenaroli, F., Harms, G. S., Dietrich, D., Dietrich, J., Rosenauer, C., Barz, M., et al. (2021) · ACS Nano · doi:10.1021/acsnano.1c08632 · Cited by 51
Tseng, C., Chang, K.-C., Yeh, M.-C., Yang, K. C., Tang, T.-P., & Lin, F. (2013) · Ceramics International · doi:10.1016/j.ceramint.2013.09.137 · Cited by 50
Varache, M., Bezverkhyy, I., Saviot, L., Bouyer, F., Baras, F., & Bouyer, F. (2014) · Journal of Non-Crystalline Solids · doi:10.1016/j.jnoncrysol.2014.10.020 · Cited by 51
Voulgari, E., Bakandritsos, A., Galtsidis, S., Zoumpourlis, V., Burke, B. P., Clemente, G. S., Cawthorne, C., Archibald, S. J., Tuček, J., Zbořil, R., et al. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.10.021 · Cited by 51
Self-assembling polymer systems for advanced treatment of cancer and inflammation
Palao‐Suay, R., Gómez‐Mascaraque, L. G., Aguilar, M. R., Vázquez‐Lasa, B., & Román, J. S. (2015) · Progress in Polymer Science · doi:10.1016/j.progpolymsci.2015.07.005 · Cited by 54
Cai, S., Xie, Y., Davies, N. M., Cohen, M. S., & Forrest, M. L. (2009) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.22016 · Cited by 49
Hu, J. Q., He, J., Cao, D., Zhang, M., & Ni, P. (2015) · Polymer Chemistry · doi:10.1039/c5py00023h · Cited by 48
A Comparison between the Nephrotoxic Profile of Gentamicin and Gentamicin Nanoparticles in Mice
Jamshidzadeh, A., Heidari, R., Mohammadi‐Samani, S., Azarpira, N., Najbi, A., Jahani, P., & Abdoli, N. (2014) · Journal of Biochemical and Molecular Toxicology · doi:10.1002/jbt.21667 · Cited by 50
“Moreover, it has been reported that some other drugs with nephrotoxic properties became less toxic when they were formulated as nanoparticles [33, 34].”
BackgroundShell crosslinked knedel-like nanoparticles for delivery of cisplatin: effects of crosslinking
Zhang, F., Elsabahy, M., Zhang, S., Lin, L. Y., Zou, J., & Wooley, K. L. (2013) · Nanoscale · doi:10.1039/c3nr34320k · Cited by 47
Saisyo, A., Nakamura, H., Fang, J. Q., Tsukigawa, K., Greish, K. F., Furukawa, H., & Maeda, H. (2015) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2015.11.032 · Cited by 47
Versatile Applications of Metallopolymers
Götz, S., Zechel, S., Hager, M. D., Newkome, G. R., & Schubert, U. S. (2021) · Progress in Polymer Science · doi:10.1016/j.progpolymsci.2021.101428 · Cited by 51
Paclitaxel and cisplatin as intravesical agents against non‐muscle‐invasive bladder cancer
Hadaschik, B. A., Borg, M. G. T., Jackson, J. K., Sowery, R. D., So, A., Burt, H. M., & Gleave, M. E. (2008) · British Journal of Urology · doi:10.1111/j.1464-410x.2008.07571.x · Cited by 46
Raj, V., & Prabha, G. (2015) · Journal of the Association of Arab Universities for Basic and Applied Sciences · doi:10.1016/j.jaubas.2015.08.001 · Cited by 45
“Chemotherapy with cisplatin is connected with some serious side effects, such as: vomiting, nephrotoxicity, ototoxicity, neuropathy, anemia and nausea (Uchino et al., 2005).”
BackgroundSaito, Y., Yasunaga, M., Kuroda, J., Koga, Y., & Matsumura, Y. (2008) · Cancer Science · doi:10.1111/j.1349-7006.2008.00806.x · Cited by 45
Self-citationImmunomicelles for advancing personalized therapy
Sawant, R. R., Jhaveri, A. M., & Torchilin, V. P. (2012) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.08.003 · Cited by 49
Song, W., Tang, Z., Zhang, D., Burton, N., Driessen, W. H. P., & Chen, X. (2014) · RSC Advances · doi:10.1039/c4ra09735a · Cited by 44
Nano-sized drug carriers: Extravasation, intratumoral distribution, and their modeling
Nichols, J. W., Sakurai, Y., Harashima, H., & Bae, Y. H. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.08.003 · Cited by 44
“The liver is a major clearance organ for most drug carrier systems in clinical trials, such as micelles (NC-6004) [27], linear polymers (PK1) [28], albumin-bound paclitaxel (Abraxane®) [29] and Doxil® [30], at least in rodents.”
BackgroundMistry, P., Neagu, D. C., Trundle, P. R., & Vessey, J. D. (2015) · Soft Computing · doi:10.1007/s00500-015-1925-9 · Cited by 46
“Vehicles have also been designed and formulated to mitigate unwanted toxicities associated with drugs that are considered highly toxic (Huo et al. 2010; Uchino et al. 2005; Kelava et al. 2010).”
BackgroundSynthesis and Self-Assembly of RGD-Functionalized PEO-PB Amphiphiles
Zupancich, J. A., Bates, F. S., & Hillmyer, M. A. (2009) · Biomacromolecules · doi:10.1021/bm900149b · Cited by 41
Lipid, polymeric, inorganic-based drug delivery applications for platinum-based anticancer drugs
Boztepe, T., Castro, G. R., & León, I. E. (2021) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2021.120788 · Cited by 47
Yamamoto, Y., Hyodo, I., Takigahira, M., Koga, Y., Yasunaga, M., Harada, M., Hayashi, T., Kato, Y., & Matsumura, Y. (2014) · International Journal of Cancer · doi:10.1002/ijc.28651 · Cited by 40
“These findings were consistent with the findings of our previous study.(21,35) From these results, the combined micelle therapy could be expected to prolong the effective treatment duration, consequently leading to survival prolongation.”
BackgroundResultSelf-citationDevelopment of Electrochromic Devices
Pawlicka, A. (2009) · Recent Patents on Nanotechnology · doi:10.2174/187221009789177821 · Cited by 44
Miller, T., Hill, A., Uezguen, S., Weigandt, M., & Goepferich, A. (2012) · Biomacromolecules · doi:10.1021/bm3002045 · Cited by 37
Stimuli Responsive Peptide Conjugated Polymer Nanoparticles
Knoop, R. J. I., de Geus, M., Habraken, G. J. M., Koning, C. E., Menzel, H., & Heise, A. (2010) · Macromolecules · doi:10.1021/ma100327p · Cited by 38
Yamamoto, Y., Hyodo, I., Koga, Y., Tsumura, R., Sato, R., Obonai, T., Fuchigami, H., Furuya, F., Yasunaga, M., Harada, M., et al. (2015) · Cancer Science · doi:10.1111/cas.12645 · Cited by 40
Self-citationMiki, K., Kuramochi, Y., Oride, K., Inoue, S., Harada, H., Hiraoka, M., & Ohe, K. (2009) · Bioconjugate Chemistry · doi:10.1021/bc800449s · Cited by 40
Rosic, G. L., Selaković, D., Joksimović, J., Srejovic, I. M., Zivkovic, V. I., Tatalović, N., Oreščanin-Dušić, Z., Mitrović, S., Ilić, M., & Jakovljevic, V. L. (2015) · Toxicology Letters · doi:10.1016/j.toxlet.2015.11.028 · Cited by 38
“performed in our study, the mean plasma concentration of total platinum content was between 10 and 1 mg/L, with a gradual decrease until 10 h after the injection (Uchino et al., 2005).”
Yao, X., Xie, C., Chen, W., Yang, C., Wu, W., & Jiang, X. (2015) · Biomacromolecules · doi:10.1021/acs.biomac.5b00479 · Cited by 38
Abolmaali, S. S., Tamaddon, A. M., Salmanpour, M., Mohammadi, S., & Dinarvand, R. (2017) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2017.04.009 · Cited by 39
Zhang, J., Li, S., & Li, X. (2009) · Recent Patents on Nanotechnology · doi:10.2174/187221009789177803 · Cited by 42
“Several formulations based on polymeric micelles have been intensively studied for cancer therapy and their efficacy has been well demonstrated [17-20].”
BackgroundLi, G., Che, X., Wang, S., Liu, D., Xie, D., Jiang, B., Zheng, Z., Xu, Z., & Wu, G. (2025) · Annals of Medicine · doi:10.1080/07853890.2024.2447403 · Cited by 55
Yao, H., Cui, P., Xu, D., Liu, Y., Tian, Q., & Zhang, F. (2017) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2017.09.043 · Cited by 39
Chen, Q., Luo, L., Xue, Y., Han, J., Liu, Y., Zhang, Y. X., Yin, T., Wang, L., Cun, D., Gou, J., et al. (2019) · Acta Biomaterialia · doi:10.1016/j.actbio.2019.05.007 · Cited by 38
Polymeric Micelles for the Delivery of Poorly Soluble Drugs
Biswas, S., Vaze, O. S., Movassaghian, S., & Torchilin, V. P. (2013) · Wiley eBooks · doi:10.1002/9781118444726.ch14 · Cited by 41
Preclinical and clinical studies of anticancer drug-incorporated polymeric micelles
Matsumura, Y. (2007) · Journal of Drug Targeting · doi:10.1080/10611860701499888 · Cited by 37
“On the other hand, the IC50 values of NK012 were a little higher than those of SN-38, similar to the cytotoxic feature also reported in a previous study about micellar drugs (Uchino et al. 2005).”
ResultSelf-citationA novel micelle-encapsulated platinum(II) anticancer agent
Jadhav, V. B., Jun, Y. J., Song, J. H., Park, M. K., Oh, J. H., Chae, S. W., Kim, I.-S., Choi, S.-J., Lee, H. J., & Sohn, Y. S. (2010) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.07.101 · Cited by 38
Nanoparticles as Delivery Systems in Cancer Therapy
Carvalho, A., Fernandes, A. R., & Baptista, P. V. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-814029-1.00010-7 · Cited by 46
Chiang, C., Tseng, Y., Liao, B., & Chen, S. Y. (2015) · Advanced Healthcare Materials · doi:10.1002/adhm.201400794 · Cited by 36
Metadata
- Authors
- Uchino, H., Matsumura, Y., Negishi, T., Koizumi, F., Hayashi, T., Honda, T., Nishiyama, N., Kataoka, K., Naito, S., & Kakizoe, T.
- Affiliations
- National Cancer Center Hospital East (JP)
- NanoCarrier (Japan) (JP)
- Fukushima Medical University (JP)
- The University of Tokyo (JP)
- Kyushu University (JP)
- National Cancer Centre Japan (JP)
- Corresponding author
- Matsumura, Y
- Venue
- British Journal of Cancer
- Published
- 2005-09
- Volume
- 93
- Issue
- 6
- Pages
- 678-687
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- PMC
- PMC2361620
- OpenAlex
- W1974920077
- Cited by
- 430
- References
- 37
- Citations by year
- 2026: 10 · 2025: 7 · 2024: 9 · 2023: 12 · 2022: 20 · 2021: 22 · 2020: 21 · 2019: 20 · 2018: 9 · 2017: 34 · 2016: 27 · 2015: 35 · 2014: 39 · 2013: 32 · 2012: 29
- FWCI
- 5.45
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-sa
- www.springer.com/tdm (unspecified)
- Locations
- British Journal of Cancer (publishedVersion, cc-by-nc-sa)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- Ministry of Health, Labour and Welfare
- Topics
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Chemotherapy-induced organ toxicity mitigation
- Health Sciences › Medicine › Oncology › Metal complexes synthesis and properties
- Keywords
- cisplatin, polymeric micelles, nephrotoxicity, neurotoxicity, hepatotoxicity, sensory nerve conduction velocity, antitumour activity, pharmacokinetics, drug toxicity reduction
- MeSH terms
- Animals, Antineoplastic Agents, Body Weight, Brain, Cisplatin, Drug Carriers, Female, Humans, Kidney, Kidney Diseases, Liver, Mice, Inbred BALB C, Mice, Nude, Micelles, Polyethylene Glycols, Tumor Cells, Cultured, Rats, Sprague-Dawley, Neurotoxicity Syndromes, Mice, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.